Katy Rezvani Highlights CRISPR Advances in CAR NK Cells
Katy Rezvani, Vice President and Head of Institute for Cell Therapy Discovery and Innovation at MD Anderson Cancer Center, shared a post on LinkedIn about a paper by Alexander Biederstädt et al. published on Cancer Cell:
“Delighted to share our paper published today in Cancer Cell, co-authored by Dr. Alexander Biederstädt and Dr. Rafet Basar, reporting the first genome wide CRISPR screen in primary cord blood CAR NK cells. We identify key genetic checkpoints including MED12, ARIH2, and CCNC, whose ablation enhances NK cell anti-tumor activity. Huge congratulations to Alex and Rafet, and to all our collaborators and co-authors for making this work possible.”
Title: Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Authors: Alexander Biederstädt, Rafet Basar, Jeong-Min Park, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Merve Dede, John Watts, Sunil Acharya, Donghai Xiong, Bin Liu, May Daher, Hind Rafei, Pinaki Banerjee, Ping Li, Sanjida Islam, Huihui Fan, Mayra Shanley, Jingling Jin, Bijender Kumar, Vernikka Woods, Paul Lin, Silvia Tiberti, Ana Karen Nunez Cortes, Xin Ru Jiang, Inci Biederstädt, Patrick Zhang, Ye Li, Seema Rawal, Enli Liu, Luis Muniz-Feliciano, Gary M. Deyter, Elizabeth J. Shpall, Natalie Wall Fowlkes, Ken Chen, Katayoun Rezvani
Read the full article.
More posts featuring Katy Rezvani on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023